About ETS translocation variant 3
ETS translocation variant 3 (ETV3) is a protein
from Homo sapiens identified by UniProt accession
P41162, 512 residues long.
MolForge cross-references it against 0 known binders and
42 disease associations.
Target properties
| Protein name | ETS translocation variant 3 |
| UniProt accession | P41162 |
| Gene | ETV3 |
| Organism | Homo sapiens |
| Length | 512 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (42)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.53
- prostate carcinoma · score 0.24
- systemic lupus erythematosus · score 0.17
- neutrophil count · score 0.05
- Hodgkins lymphoma · score 0.04
- blood protein measurement · score 0.04
- neoplasm · score 0.01
- anaplastic large cell lymphoma · score 0.01
- metastatic melanoma · score 0.01
- chronic lymphocytic leukemia · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P41162-F1 | alphafold | PREDICTED | 54.67 | — |
Amino-acid sequence (512 residues)
MKAGCSIVEK PEGGGGYQFP DWAYKTESSP GSRQIQLWHF ILELLQKEEF RHVIAWQQGE YGEFVIKDPD EVARLWGRRK CKPQMNYDKL SRALRYYYNK RILHKTKGKR FTYKFNFNKL VMPNYPFINI RSSGVVPQSA PPVPTASSRF HFPPLDTHSP TNDVQPGRFS ASSLTASGQE SSNGTDRKTE LSELEDGSAA DWRRGVDPVS SRNAIGGGGI GHQKRKPDIM LPLFARPGMY PDPHSPFAVS PIPGRGGVLN VPISPALSLT PTIFSYSPSP GLSPFTSSSC FSFNPEEMKH YLHSQACSVF NYHLSPRTFP RYPGLMVPPL QCQMHPEEST QFSIKLQPPP VGRKNRERVE SSEESAPVTT PTMASIPPRI KVEPASEKDP ESLRQSAREK EEHTQEEGTV PSRTIEEEKG TIFARPAAPP IWPSVPISTP SGEPLEVTED SEDRPGKEPS APEKKEDALM PPKLRLKRRW NDDPEARELS KSGKFLWNGS GPQGLATAAA DA
Explore ETS translocation variant 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets